Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0557. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R known ✓ | Q15761 | 20/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0557 SCHEMBL742900 | 1.00 | NPY5R (1.00) | NPY5RDRD3 | |
| Mk-0557 SCHEMBL31670317 | 1.00 | NPY5R (1.00) | NPY5RDRD3 | |
| Mk-0557 SCHEMBL13465189 | 1.00 | NPY5R (1.00) | NPY5RDRD3 | |
| Mk-0557 SCHEMBL742899 | 1.00 | NPY5R (1.00) | NPY5RDRD3 | |
| SCHEMBL4719516 | 0.90 | NPY5R (0.82) | NPY5RDRD3 | |
| SCHEMBL4719512 | 0.90 | NPY5R (0.82) | NPY5RDRD3 | |
| SCHEMBL13865582 | 0.90 | NPY5R (0.81) | NPY5RDRD3 | |
| SCHEMBL5622603 | 0.89 | NPY5R (0.80) | NPY5RDRD3 | |
| SCHEMBL5622607 | 0.89 | NPY5R (0.80) | NPY5RDRD3 | |
| SCHEMBL917791 | 0.88 | NPY5R (1.00) | NPY5RDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4595966-A1 | USE OF NPY/Y5R INHIBITOR IN TREATING LIVER METASTASIS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2025-08-06 | — | — | EP | claimed |
| US-12544360-B2 | Pharmaceutical composition for preventing or treating coronavirus disease-19 | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-02-10 | — | — | US | disclosed |
| EP-4081244-B1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4595966-A1 | USE OF NPY/Y5R INHIBITOR IN TREATING LIVER METASTASIS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2025-08-06 | — | — | EP | disclosed |
| US-12281109-B2 | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes | MERCK SHARP & DOHME LLC (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230285514-A1 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230270825-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20220072011-A1 | TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF | ALLERGAN SALES, LLC (US) | 2022-03-10 | — | — | US | disclosed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| EP-1912642-B1 | A CRYSTALLINE FORM OF A NPY5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| US-7700611-B2 | Synthesis and crystalline forms of NPY5 antagonist | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700611-B2 | Synthesis and crystalline forms of NPY5 antagonist | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2009111868-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-17 | — | — | WO | disclosed |
| US-20090124648-A1 | Synthesis and Crystalline Forms of Npy5 Antagonist | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20090124648-A1 | Synthesis and Crystalline Forms of Npy5 Antagonist | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| WO-2007016028-A2 | SYNTHESIS AND CRYSTALLINE FORMS OF NPY5 ANTAGONIST | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281109-B2 | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes | HDAC3, HDAC1, HDAC2 | NPY5R 2574/4885DRD3 3856/4885 |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | NPY5R 260/4885DRD3 1997/4885 |
| US-20090124648-A1 | Synthesis and Crystalline Forms of Npy5 Antagonist | NPY5R, SSTR5, NPY1R | NPY5R 1/4885DRD3 706/4885 |
| US-20230270825-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GIPR, GCGR | NPY5R 31/4885DRD3 2500/4885 |
| US-12544360-B2 | Pharmaceutical composition for preventing or treating coronavirus disease-19 | SARS1, TMPRSS2, PLIN1 | NPY5R 3686/4885DRD3 2946/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | NPY5R 1/4885DRD3 3628/4885 |
| US-20230285514-A1 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GIPR, GCGR | NPY5R 68/4885DRD3 4083/4885 |
| US-20220072011-A1 | TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF | FABP4, LIPC, SLC10A1 | NPY5R 2381/4885DRD3 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.